Story perspectives

Revolutionary Galleri Test Detects 50+ Cancers Early in Canada

10/21/2025

Summary

Story summary

Medcan launched the Galleri Multi-Cancer Early Detection Test in Canada, enabling detection of over 50 cancer types from one blood draw.
The Galleri test was developed by GRAIL to identify cancer signals before symptoms appear, potentially improving treatment outcomes.
PATHFINDER 2, involving nearly 36,000 participants, reported 99.6% specificity and 61.6% positive predictive value, with experts noting that more studies are needed to assess mortality rates.

1 of 1

Story summary

Medcan launched the Galleri Multi-Cancer Early Detection Test in Canada, enabling detection of over 50 cancer types from one blood draw.
The Galleri test was developed by GRAIL to identify cancer signals before symptoms appear, potentially improving treatment outcomes.
PATHFINDER 2, involving nearly 36,000 participants, reported 99.6% specificity and 61.6% positive predictive value, with experts noting that more studies are needed to assess mortality rates.